[
    [
        {
            "time": "2018-11-15",
            "original_text": "Novartis abandons effort for U.S. approval of biosimilar rituximab",
            "features": {
                "keywords": [
                    "Novartis",
                    "abandons",
                    "U.S.",
                    "approval",
                    "biosimilar",
                    "rituximab"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-12-03",
            "original_text": "Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology",
            "features": {
                "keywords": [
                    "Novartis",
                    "ASH",
                    "SABCS",
                    "pipeline",
                    "portfolio",
                    "hematology",
                    "oncology"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-26",
            "original_text": "AbbVie's (ABBV) Q3 Earnings Beat Estimates, 2018 EPS View Up",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Q3",
                    "Earnings",
                    "Beat",
                    "Estimates",
                    "EPS",
                    "View",
                    "Up"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-11-08",
            "original_text": "Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates",
            "features": {
                "keywords": [
                    "Conatus",
                    "Q3",
                    "Loss",
                    "In",
                    "Line",
                    "Revenues",
                    "Lag",
                    "Estimates"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 6,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-11-08",
            "original_text": "Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates",
            "features": {
                "keywords": [
                    "Conatus",
                    "Q3",
                    "Loss",
                    "In",
                    "Line",
                    "Revenues",
                    "Lag",
                    "Estimates"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 6,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-11-20",
            "original_text": "A Look at Merck’s Diabetes and Women’s Health Business",
            "features": {
                "keywords": [
                    "Merck",
                    "Diabetes",
                    "Women’s",
                    "Health",
                    "Business"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 4,
                "Source_Recency": 5
            }
        }
    ]
]